tert-Butyl 4-aminophenethylcarbamate CAS:94838-59-2

tert-Butyl 4-aminophenethylcarbamate

Chemical Name:tert-Butyl 4-aminophenethylcarbamate
CAS.NO:94838-59-2
Synonyms:tert-Butyl 4-aminophenethylcarbamate
tert-butyl N-[2-(4-aminophenyl)ethyl]carbamate
4-[2-(Boc-amino)ethyl]aniline
[2-(4-Amino-phenyl)-ethyl]-carbamic acid tert-butyl ester
2-Methyl-2-propanyl [2-(4-aminophenyl)ethyl]carbamate
tert-Butyl-2-(4-aminophenyl)ethylcarbamate
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 396.8±25.0 °C at 760 mmHg
Molecular Formula C13H20N2O2
Molecular Weight 236.310
Flash Point 193.8±23.2 °C
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Mirabegron(CAS:223673-61-8).



We are professional tert-Butyl 4-aminophenethylcarbamate manufacturer and tert-Butyl-2-(4-aminophenyl)ethylcarbamate supplier in China, We offer quality tert-Butyl 4-aminophenethylcarbamate you can fully trust, also we have India factory and producer of 2-Methyl-2-propanyl [2-(4-aminophenyl)ethyl]carbamate,Pls send inquiry of tert-Butyl-2-(4-aminophenyl)ethylcarbamate to info@nbinno.com if you have any interests, thank you!


Related News: Active pharmaceutical ingredients directly impact disease.2-Chloro-4-(trifluoromethyl)pyridine CAS:81565-18-6 Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients.Ethyl 4-bromobutyrate The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).2,5-Dimethyl pyrazine Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them.